National Cancer Institute; Notice of Closed Meeting, 2253 [06-303]

Download as PDF Federal Register / Vol. 71, No. 9 / Friday, January 13, 2006 / Notices 2253 before the release of the samples. This agreement will contain the conditions for use of the DNA as stated in this document and as agreed upon by the investigators and CDC. A key component of this agreement is that no attempt will be made to link the results of the proposed research to any other data, including, but not limited to, the NHANES III public use data set. Also, the investigator agrees that the samples cannot be used for commercial purposes. A list of genes generated from the testing of the NHANES III samples will be made available to the public for potential solicitation of proposal for secondary data analysis, six months after the data is sent to the RDC. These secondary data analysis proposals must also be reviewed by the NHANES Genetics Technical Panel and the ERB. 2. Clayton EW, Steinberg KK, Khoury MJ, et al. Informed consent for genetic research on stored tissue samples. JAMA 1995;274:1786–1792. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: December 21, 2005. James D. Seligman, Associate Director for Program Services, Centers for Disease Control and Prevention. [FR Doc. E5–8104 Filed 1–12–06; 8:45 am] National Cancer Institute; Notice of Closed Meeting Progress Reports AGENCY: A progress report will be submitted annually. CDC/NCHS ERB continuation reports are also required annually. HHS. BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration University of Arkansas/Food and Drug Administration Food Labeling; Public Workshop; Correction Food and Drug Administration, Notice of public workshop; correction. ACTION: Disposition of Results and Samples No DNA samples provided can be used for any purpose other than those specifically requested in the proposal and approved by the Genetics Technical Panel, the Secondary Review Committee and the NHANES ERB. No sample can be shared with others, including other investigators, unless specified in the proposal and so approved. Any unused samples must be destroyed upon completion of the approved project, unless a request is submitted and approved under Category D. Researchers requesting DNA samples for age-racegender studies and special studies will be required to provide NCHS with the results of all DNA tests performed for each anonymized sample. These results, once returned to NCHS, will be part of the public domain. Therefore, ample time will be given to the investigator to publish results prior to reporting the results to NCHS. Send Requests for Information hsrobinson on PROD1PC70 with NOTICES Ms. Kika Oraegbu, Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Room 4207, Hyattsville, MD 20782, Phone: 301–458–4367, Fax: 301–458–4028, Email: KDO1@cdc.gov. References 1. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–94. National Center for Health Statistics. Vital Health Stat (32) 1994. VerDate Aug<31>2005 18:33 Jan 12, 2006 Jkt 208001 SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of January 4, 2006 (71 FR 349). The document announced a public workshop entitled ‘‘UA/FDA Food Labeling Workshop.’’ The document was published with a typographical error in the SUPPLEMENTARY INFORMATION section. This document corrects that error. FOR FURTHER INFORMATION CONTACT: David Arvelo, Food and Drug Administration, 4040 North Central Expressway, suite 900, Dallas, TX 75204, 214–253–4952, FAX: 214–243– 4970. In FR Doc. E5–8225, appearing on page 349, in the Federal Register of Wednesday, January 4, 2006, the following correction is made: 1. On page 349, in the third column, the second sentence under SUPPLEMENTARY INFORMATION is corrected to read: ‘‘This public workshop is being held in response to the large volume of food labeling inquiries from small food manufacturers and startups originating from the area covered by the FDA Dallas District Office.’’ SUPPLEMENTARY INFORMATION: Dated: January 9, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6–268 Filed 1–12–06; 8:45 am] BILLING CODE 4160–01–S PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Synthesis and High-Throughput Screening of In Vivo Cancer Molecular Imaging Agents. Date: February 24, 2006. Time: 12 p.m. to 4:30 p.m. Agenda: To review and evaluate contract proposals. Place: Executive Plaza North, 6130 Executive Boulevard, Room C, Rockville, MD 20852. (Telephone Conference Call). Contact Person: Kenneth L Bielat, PhD, Scientific Review Administrator, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 7147, Bethesda, MD 20892. (301) 496–7576. bielatk@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 5, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–303 Filed 1–12–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as E:\FR\FM\13JAN1.SGM 13JAN1

Agencies

[Federal Register Volume 71, Number 9 (Friday, January 13, 2006)]
[Notices]
[Page 2253]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-303]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Synthesis and High-Throughput Screening of In Vivo Cancer 
Molecular Imaging Agents.
    Date: February 24, 2006.
    Time: 12 p.m. to 4:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: Executive Plaza North, 6130 Executive Boulevard, Room C, 
Rockville, MD 20852. (Telephone Conference Call).
    Contact Person: Kenneth L Bielat, PhD, Scientific Review 
Administrator, Division of Extramural Activities, National Cancer 
Institute, National Institutes of Health, 6116 Executive Boulevard, 
Room 7147, Bethesda, MD 20892. (301) 496-7576. bielatk@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)


    Dated: January 5, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-303 Filed 1-12-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.